EMA Agrees Monovalent XBB Vaccines Best For Coming COVID-19 Campaigns
Executive Summary
The European Medicines Agency says it is talking with international partners and pharmaceutical companies about the epidemiological situation with SARS-CoV-2 and how authorized COVID-19 vaccines can best be adapted to emerging variants.
You may also be interested in...
SK Bioscience Pulls EU Filing For COVID Jab As Regulators Shift Focus To XBB Vaccines
The European Medicines Agency’s CHMP was set to adopt opinions on SK Bioscience’s COVID-19 vaccine and Mycovia/Gedeon’s Vivjoa for vulvovaginal candidiasis during its September meeting, but both marketing authorization filings were voluntarily withdrawn.
COVID-19 Has ‘Permanently Changed’ How The EMA Works
During the pandemic, the EU drugs regulator became more flexible and agile and went beyond the formal boundaries of its mandate, says its executive director Emer Cooke, who also warns of the need for the agency to retain the trust of the public.
International Regulators Focus On Omicron XBB For Monovalent COVID-19 Vaccine
A workshop led by the European Medicines Agency and the US Food and Drug Administration sought to reach alignment on adapting COVID-19 vaccines to emerging virus variants.